Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

PlexusDx vs Remi Meds

PlexusDx
Graded #162

Higher grade

vs+19.300000000000004
Remi Meds
Graded #493

Lower grade

The verdict

PlexusDx takes it — 67.7/100 to 48.4/100.

PlexusDx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. PlexusDx (plexusdx.com) is a US GLP-1 telehealth platform offering compounded weight-loss medications with licensed providers in all 50 states.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuePlexusDx +40
74
34
Dose & formulationPlexusDx +10
64
54
Clinical oversightPlexusDx +20
74
54
Labs & monitoringPlexusDx +2
52
50
FulfillmentPlexusDx +25
78
53
Contract termsEven
55
55
PlexusDx · left barRemi Meds · right bar

The numbers

MetricPlexusDxRemi Meds
WeighScore67.7/10048.4/100
GradeCC
Scorecard rank#162#493
Semaglutide$149/mo (starting dose, compounded)$249/mo (0.25 mg dose, compounded)
Tirzepatide$249/mo (starting dose, compounded)$349/mo (2.25 mg dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
PlexusDx

Graded #162 · C

Strengths

  • Licensed providers available in all 50 states
  • Range of options including low-cost microdose GLP-1 from $129/mo
  • Optional Precision Peptide genetic panel adds a personalization angle
  • Independent clinician review via state-licensed telehealth platform
  • Compounded medications from state-licensed pharmacies

Where it loses points

  • Compounded medications only; no FDA-approved brand options
  • Specific compounding pharmacies not named
  • Genetic-panel upsell may not add clinical value for everyone
  • Tirzepatide pricing from $249/mo is higher than budget rivals
  • No insurance accepted
Remi Meds

Graded #493 · C

Strengths

  • Names its compounding pharmacy (Strive Pharmacy, Gilbert AZ) — stronger transparency than peers
  • LegitScript verification badge on the homepage
  • Publishes 503A FDCA compliance language on the tirzepatide page
  • Per-dose-tier pricing fully shown — no 'as low as' floor-only obfuscation
  • Operating corporate entity disclosed (T-C Health Co)

Where it loses points

  • No named medical director, founder, or physician on any public page
  • States served not listed — 'nationwide' claim with no per-state detail
  • Clinical care runs through Beluga Health, a network a 2026 StatNews analysis tied to many FDA-warned GLP-1 companies (Remi Meds itself not FDA-warned)
  • Year founded and corporate history are opaque
  • Two phone numbers and a secondary 'Rekindle RX' email hint at shared infrastructure

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard